{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:11:29Z","timestamp":1791983489169,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2012-01981"],"award-info":[{"award-number":["2012-01981"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2017-00932"],"award-info":[{"award-number":["2017-00932"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","award":["5321-9416"],"award-info":[{"award-number":["5321-9416"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Progesterone receptor antagonists such as mifepristone have emerged as candidates for breast cancer prevention, particularly in high-risk populations such as\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      pathogenic variant carriers. However, their impact on endometrial safety remains insufficiently characterized, raising concerns about unopposed oestrogen stimulation in the setting of impaired DNA repair. This study reports secondary outcomes evaluating short-term endometrial effects of mifepristone in this high-risk population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We previously conducted a randomized, double-blind, placebo-controlled trial (NCT01898312) involving 45 premenopausal women with\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      pathogenic variants. Participants received mifepristone (50\u2009mg every other day, n\u2009=\u200930) or a non-hormonal comparator (n\u2009=\u200915) for three months. Here we present secondary outcomes from the trial: Paired endometrial biopsies from a subset of 14 participants were analysed using transcriptomic, DNA methylation, and cell-type deconvolution methods. Statistical comparisons were performed using paired and unpaired Wilcoxon tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here we show that mifepristone induces amenorrhea in all treated participants without increasing epithelial cell proportions, the compartment most relevant to endometrial carcinogenesis. Multi-omics analyses reveal no molecular signatures consistent with oncogenic transformation. DNA methylation and gene expression indices associated with endometrial cancer remain stable after treatment, even after adjusting for age and cell composition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Short-term mifepristone exposure does not produce molecular changes linked to endometrial carcinogenesis in\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      pathogenic variant\u00a0carriers. These findings provide important safety data for the future development of progesterone receptor modulators in cancer prevention. Long-term studies are needed to confirm these observations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-026-01412-0","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:24:24Z","timestamp":1770827064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Short-term hormonal modulation with mifepristone does not induce oncogenic changes in the endometrium of BRCA1\/2 pathogenic variant\u00a0carriers"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-8380","authenticated-orcid":false,"given":"Martin","family":"Widschwendter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1572-498X","authenticated-orcid":false,"given":"Chiara","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Fatih","family":"Rasul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nageswara Rao","family":"Boggavarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6540-8443","authenticated-orcid":false,"given":"Elisa","family":"Redl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Utj\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique","family":"Fl\u00f6ter R\u00e5destad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6516-1444","authenticated-orcid":false,"given":"Kristina","family":"Gemzell- Danielsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-2364","authenticated-orcid":false,"given":"Twana","family":"Alkasalias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"1412_CR1","first-page":"144","volume":"27","author":"PJD Bouic","year":"2023","unstructured":"Bouic, P. J. D. Endometriosis and infertility: the hidden link between endometritis, hormonal imbalances and immune dysfunctions preventing implantation!. J. Bras. Reprod. Assist 27, 144\u2013146 (2023).","journal-title":"J. Bras. Reprod. Assist"},{"key":"1412_CR2","doi-asserted-by":"crossref","unstructured":"Steinbuch, S. C., Luess, A. M., Eltrop, S., Goette, M. & Kiesel, L. Endometriosis-associated ovarian cancer: from molecular pathologies to clinical relevance. Int. J. Mol. Sci. 25, 4306 (2024).","DOI":"10.3390\/ijms25084306"},{"key":"1412_CR3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00404-021-06380-5","volume":"306","author":"LK Nees","year":"2022","unstructured":"Nees, L. K. et al. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch. Gynecol. Obstet. 306, 407\u2013421 (2022).","journal-title":"Arch. Gynecol. Obstet."},{"key":"1412_CR4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12672-019-0358-9","volume":"10","author":"AC Rodriguez","year":"2019","unstructured":"Rodriguez, A. C., Blanchard, Z., Maurer, K. A. & Gertz, J. Estrogen signaling in endometrial cancer: a key oncogenic pathway with several open questions. Horm. Cancer 10, 51\u201363 (2019).","journal-title":"Horm. Cancer"},{"key":"1412_CR5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.tem.2011.01.005","volume":"22","author":"S Yang","year":"2011","unstructured":"Yang, S., Thiel, K. W. & Leslie, K. K. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrin Met. 22, 145\u2013152 (2011).","journal-title":"Trends Endocrin Met."},{"key":"1412_CR6","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1412_CR7","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature09027","volume":"465","author":"ML Asselin-Labat","year":"2010","unstructured":"Asselin-Labat, M. L. et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465, 798\u2013802 (2010).","journal-title":"Nature"},{"key":"1412_CR8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2011.09.021","volume":"357","author":"SD Axlund","year":"2012","unstructured":"Axlund, S. D. & Sartorius, C. A. Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol. Cell Endocrinol. 357, 71\u201379 (2012).","journal-title":"Mol. Cell Endocrinol."},{"key":"1412_CR9","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S1470-2045(13)70448-0","volume":"14","author":"M Widschwendter","year":"2013","unstructured":"Widschwendter, M. et al. The sex hormone system in carriers of BRCA1\/2 mutations: a case-control study. Lancet Oncol. 14, 1226\u20131232 (2013).","journal-title":"Lancet Oncol."},{"key":"1412_CR10","volume":"14","author":"TE Bartlett","year":"2022","unstructured":"Bartlett, T. E. et al. Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. Genome Med 14, 64 (2022).","journal-title":"Genome Med"},{"key":"1412_CR11","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1158\/0008-5472.CAN-03-3852","volume":"64","author":"M Widschwendter","year":"2004","unstructured":"Widschwendter, M. et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64, 3807\u20133813 (2004).","journal-title":"Cancer Res"},{"key":"1412_CR12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/endrev\/bnz001","volume":"41","author":"B Trabert","year":"2020","unstructured":"Trabert, B., Sherman, M. E., Kaman, N. & Stanczyk, F. Z. Progesterone and breast cancer. Endocr. Rev. 41, 320\u2013344 (2020).","journal-title":"Endocr. Rev."},{"key":"1412_CR13","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-023-01661-0","volume":"25","author":"HJT Coelingh Bennink","year":"2023","unstructured":"Coelingh Bennink, H. J. T. et al. Progesterone from ovulatory menstrual cycles is an important cause of breast cancer. Breast Cancer Res. 25, 60 (2023).","journal-title":"Breast Cancer Res."},{"key":"1412_CR14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41420-023-01484-0","volume":"9","author":"L Yang","year":"2023","unstructured":"Yang, L. et al. TRPS1 regulates the opposite effect of progesterone via RANKL in endometrial carcinoma and breast carcinoma. Cell Death Discov. 9, 185 (2023).","journal-title":"Cell Death Discov."},{"key":"1412_CR15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","volume":"468","author":"E Gonzalez-Suarez","year":"2010","unstructured":"Gonzalez-Suarez, E. et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468, 103 (2010).","journal-title":"Nature"},{"key":"1412_CR16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nm.4118","volume":"22","author":"E Nolan","year":"2016","unstructured":"Nolan, E. et al. RANK ligand as a potential target for breast cancer prevention in -mutation carriers. Nat. Med. 22, 933 (2016).","journal-title":"Nat. Med."},{"key":"1412_CR17","doi-asserted-by":"crossref","unstructured":"Wang, H. C. & Lee, W. S. Molecular mechanisms underlying progesterone-enhanced breast cancer cell migration. Sci. Rep. 6, 31509 (2016).","DOI":"10.1038\/srep31509"},{"key":"1412_CR18","doi-asserted-by":"crossref","unstructured":"Wetendorf, M. et al. Constitutive expression of progesterone receptor isoforms promotes the development of hormone-dependent ovarian neoplasms. Sci. Signal 13, eaaz9646 (2020).","DOI":"10.1126\/scisignal.aaz9646"},{"key":"1412_CR19","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/clinem\/dgab195","volume":"106","author":"LJ Mauro","year":"2021","unstructured":"Mauro, L. J. et al. Progesterone receptors promote quiescence and ovarian cancer cell phenotypes via DREAM in p53-mutant fallopian tube models. J. Clin. Endocr. Metab. 106, 1929\u20131955 (2021).","journal-title":"J. Clin. Endocr. Metab."},{"key":"1412_CR20","doi-asserted-by":"crossref","unstructured":"Bassette, E. & Ducie, J. A. Endometrial cancer in reproductive-aged females: etiology and pathogenesis. Biomedicines 12, 886 (2024).","DOI":"10.3390\/biomedicines12040886"},{"key":"1412_CR21","doi-asserted-by":"crossref","unstructured":"Shetty, C. et al. Risk of gynecological cancers in women with polycystic ovary syndrome and the pathophysiology of association. Cureus J. Med. Sci. 15, e37266 (2023).","DOI":"10.7759\/cureus.37266"},{"key":"1412_CR22","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/jog.15653","volume":"49","author":"Y Inayama","year":"2023","unstructured":"Inayama, Y. et al. Hormone replacement therapy and cancer risks in perimenopausal women: a retrospective cohort study using a Japanese claims database. J. Obstet. Gynaecol. Res. 49, 1805\u20131814 (2023).","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"1412_CR23","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","volume":"101","author":"J Donnez","year":"2014","unstructured":"Donnez, J. et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil. Steril. 101, 1565\u2013U1405 (2014).","journal-title":"Fertil. Steril."},{"key":"1412_CR24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2015.09.032","volume":"105","author":"J Donnez","year":"2016","unstructured":"Donnez, J. et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil. Steril. 105, 165 (2016).","journal-title":"Fertil. Steril."},{"key":"1412_CR25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PGP.0b013e318251035b","volume":"31","author":"ARW Williams","year":"2012","unstructured":"Williams, A. R. W., Bergeron, C., Barlow, D. H. & Ferenczy, A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J. Gynecol. Pathol. 31, 556\u2013569 (2012).","journal-title":"Int J. Gynecol. Pathol."},{"key":"1412_CR26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","volume":"21","author":"GL Mutter","year":"2008","unstructured":"Mutter, G. L. et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod. Pathol. 21, 591\u2013598 (2008).","journal-title":"Mod. Pathol."},{"key":"1412_CR27","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa1715726","volume":"378","author":"CA Schreiber","year":"2018","unstructured":"Schreiber, C. A. et al. Mifepristone pretreatment for the medical management of early pregnancy loss. N. Engl. J. Med. 378, 2161\u20132170 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1412_CR28","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/AOG.0000000000004376","volume":"137","author":"N Hamdaoui","year":"2021","unstructured":"Hamdaoui, N., Cardinale, C., Fabre, C., Baumstarck, K. & Agostini, A. Pain associated with cervical priming for first-trimester surgical abortion: a randomized controlled trial. Obstet. Gynecol. 137, 1055\u20131060 (2021).","journal-title":"Obstet. Gynecol."},{"key":"1412_CR29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.contraception.2005.03.011","volume":"72","author":"JT Henderson","year":"2005","unstructured":"Henderson, J. T., Hwang, A. C., Harper, C. C. & Stewart, F. H. Safety of mifepristone abortions in clinical use. Contraception 72, 175\u2013178 (2005).","journal-title":"Contraception"},{"key":"1412_CR30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0015-0282(16)58022-4","volume":"65","author":"LM Kettel","year":"1996","unstructured":"Kettel, L. M. et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil. Steril. 65, 23\u201328 (1996).","journal-title":"Fertil. Steril."},{"key":"1412_CR31","doi-asserted-by":"crossref","first-page":"e2317860","DOI":"10.1001\/jamanetworkopen.2023.17860","volume":"6","author":"X Che","year":"2023","unstructured":"Che, X. et al. Effect of mifepristone vs placebo for treatment of adenomyosis with pain symptoms: a randomized clinical trial. JAMA Netw. Open 6, e2317860 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1412_CR32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/phar.1202","volume":"33","author":"FH Morgan","year":"2013","unstructured":"Morgan, F. H. & Laufgraben, M. J. Mifepristone for management of Cushing\u2019s syndrome. Pharmacotherapy 33, 319\u2013329 (2013).","journal-title":"Pharmacotherapy"},{"key":"1412_CR33","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/01.AOG.0000127622.63269.8b","volume":"103","author":"J Steinauer","year":"2004","unstructured":"Steinauer, J., Pritts, E. A., Jackson, R. & Jacoby, A. F. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet. Gynecol. 103, 1331\u20131336 (2004).","journal-title":"Obstet. Gynecol."},{"key":"1412_CR34","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1093\/humrep\/del182","volume":"21","author":"N Narvekar","year":"2006","unstructured":"Narvekar, N., Critchley, H. O., Cheng, L. & Baird, D. T. Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Hum. Reprod. 21, 2312\u20132318 (2006).","journal-title":"Hum. Reprod."},{"key":"1412_CR35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/humrep\/deg022","volume":"18","author":"DT Baird","year":"2003","unstructured":"Baird, D. T. et al. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum. Reprod. 18, 61\u201368 (2003).","journal-title":"Hum. Reprod."},{"key":"1412_CR36","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/humrep\/16.6.1145","volume":"16","author":"DK Hapangama","year":"2001","unstructured":"Hapangama, D. K., Brown, A., Glasier, A. F. & Baird, D. T. Feasibility of administering mifepristone as a once a month contraceptive pill. Hum. Reprod. 16, 1145\u20131150 (2001).","journal-title":"Hum. Reprod."},{"key":"1412_CR37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.contraception.2018.05.020","volume":"98","author":"C Berger","year":"2018","unstructured":"Berger, C. et al. Molecular characterization of PRM-associated endometrial changes, PAEC, following mifepristone treatment. Contraception 98, 317\u2013322 (2018).","journal-title":"Contraception"},{"key":"1412_CR38","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/humrep\/dep100","volume":"24","author":"M Engman","year":"2009","unstructured":"Engman, M. et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum. Reprod. 24, 1870\u20131879 (2009).","journal-title":"Hum. Reprod."},{"key":"1412_CR39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1210\/jcem.87.1.8140","volume":"87","author":"A Brown","year":"2002","unstructured":"Brown, A., Cheng, L. N., Lin, S. Q. & Baird, D. T. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5\u2009mg per day for 120 days. J. Clin. Endocr. Metab. 87, 63\u201370 (2002).","journal-title":"J. Clin. Endocr. Metab."},{"key":"1412_CR40","doi-asserted-by":"crossref","unstructured":"Barrett, J. E. et al. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nat. Commun. 13, 449 (2022).","DOI":"10.1038\/s41467-021-27918-w"},{"key":"1412_CR41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nprot.2014.006","volume":"9","author":"S Picelli","year":"2014","unstructured":"Picelli, S. et al. Full-length RNA-seq from single cells using Smart-seq2. Nat. Protoc. 9, 171\u2013181 (2014).","journal-title":"Nat. Protoc."},{"key":"1412_CR42","unstructured":"Herzog C. chiaraherzog\/MifepristoneEndoMethyl: v1.0. (Zenodo, 2026)."},{"key":"1412_CR43","doi-asserted-by":"crossref","unstructured":"Makker, V. et al. Endometrial cancer. Nat. Rev. Dis. Primers 7, 88 (2021).","DOI":"10.1038\/s41572-021-00324-8"},{"key":"1412_CR44","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/ijc.34406","volume":"152","author":"JE Barrett","year":"2023","unstructured":"Barrett, J. E. et al. The WID-EC test for the detection and risk prediction of endometrial cancer. Int J. Cancer 152, 1977\u20131988 (2023).","journal-title":"Int J. Cancer"},{"key":"1412_CR45","doi-asserted-by":"crossref","unstructured":"la Torre, A., Lo Vecchio, F. & Greco, A. Epigenetic mechanisms of aging and aging-associated diseases. Cells 12, 1163 (2023).","DOI":"10.3390\/cells12081163"},{"key":"1412_CR46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41576-024-00760-8","volume":"26","author":"ZD Smith","year":"2025","unstructured":"Smith, Z. D., Hetzel, S. & Meissner, A. DNA methylation in mammalian development and disease. Nat. Rev. Genet 26, 7\u201330 (2025).","journal-title":"Nat. Rev. Genet"},{"key":"1412_CR47","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0039-128X(03)00120-X","volume":"68","author":"RM Brenner","year":"2003","unstructured":"Brenner, R. M., Slayden, O. D., Nayak, N. R., Baird, D. T. & Critchley, H. O. A role for the androgen receptor in the endometrial antiproliferative effects of progesterone antagonists. Steroids 68, 1033\u20131039 (2003).","journal-title":"Steroids"},{"key":"1412_CR48","volume":"13","author":"X Ren","year":"2022","unstructured":"Ren, X. et al. Single-cell transcriptomic analysis highlights origin and pathological process of human endometrioid endometrial carcinoma. Nat. Commun. 13, 6300 (2022).","journal-title":"Nat. Commun."},{"key":"1412_CR49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/ijgc-2022-004073","volume":"33","author":"G Bogani","year":"2023","unstructured":"Bogani, G. et al. Endometrial carcinosarcoma. Int. J. Gynecologic Cancer 33, 147\u2013174 (2023).","journal-title":"Int. J. Gynecologic Cancer"},{"key":"1412_CR50","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/ng1950","volume":"39","author":"Y Schlesinger","year":"2007","unstructured":"Schlesinger, Y. et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet 39, 232\u2013236 (2007).","journal-title":"Nat. Genet"},{"key":"1412_CR51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cell.2006.02.043","volume":"125","author":"TI Lee","year":"2006","unstructured":"Lee, T. I. et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125, 301\u2013313 (2006).","journal-title":"Cell"},{"key":"1412_CR52","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrclinonc.2018.30","volume":"15","author":"M Widschwendter","year":"2018","unstructured":"Widschwendter, M. et al. Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 292\u2013309 (2018).","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01412-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01412-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01412-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:07:22Z","timestamp":1773770842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01412-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1412"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01412-0","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}